R&D News | pharmaphorum

News

Novartis completes spin-out of Alcon eye unit

Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products.

News

Gilead files Truvada follow-up Descovy for PrEP

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six m

News

Real-world data unlocks Ibrance ok in male breast cancer

The FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based on a filing that drew heavily on post-marketing and real-world data.

News

Sanofi and Alnylam conclude research phase of RNAi alliance

Sanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance for developing drugs for rare genetic diseases.

News

Ocugen, Histogenics merge to form eye disease specialist

US biotechs Ocugen and Histogenics have announced plans to merge, creating a specialist in drugs and gene therapies for ocular diseases.

News

Regeneron and Alnylam announce $1bn collaboration

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (C

Novartis completes spin-out of Alcon eye unit

Gilead files Truvada follow-up Descovy for PrEP

Real-world data unlocks Ibrance ok in male breast cancer

Sanofi and Alnylam conclude research phase of RNAi alliance

Ocugen, Histogenics merge to form eye disease specialist

Regeneron and Alnylam announce $1bn collaboration

Electra sets terms for IPO, hoping to raise up to $347m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks